Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 5/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | SGK1 | O00141 | 3/20 | 0.53 |
| ▸ | ACLY | P53396 | 2/20 | 0.52 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.49 |
| ▸ | AXL | P30530 | 1/20 | 0.48 |
| ▸ | CCR2 | P41597 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | WDR5 | P61964 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30161062 | 0.83 | MCL1 (0.64) | MCL1HPGDTSHRSGK1ACLY | |
| SCHEMBL25450052 | 0.83 | MCL1 (0.64) | MCL1HPGDTSHRSGK1ACLY | |
| SCHEMBL2146366 | 0.80 | PTGES2 (0.61) | SGK1ACLYSLC40A1 | |
| SCHEMBL20355128 | 0.79 | CCR2 (0.43) | MCL1HPGDTSHRSGK1ACLY | |
| SCHEMBL30286647 | 0.79 | CCR2 (0.43) | MCL1HPGDTSHRSGK1ACLY | |
| SCHEMBL392182 | 0.78 | MAP2K1 (0.49) | MCL1HPGDTSHRACLYCCR2 | |
| SCHEMBL25449874 | 0.78 | MCL1 (0.64) | MCL1HPGDTSHRSGK1ACLY | |
| SCHEMBL2146100 | 0.77 | MCL1 (0.51) | MCL1TSHRACLYAXLCCR2 | |
| SCHEMBL21047032 | 0.75 | MCL1 (0.59) | MCL1HPGDTSHRSGK1ACLY | |
| SCHEMBL29683144 | 0.75 | MCL1 (0.59) | MCL1HPGDTSHRSGK1ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2521725-B1 | ARYLSULFONAMIDE PYRIDINE-PYRIDINONE DERIVATIVES, PREPARATION OF SAME, AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2013-11-27 | — | — | EP | disclosed |
| US-20130178472-A1 | ARYLSULFONAMIDE PYRIDINE-PYRIDINONE DERIVATIVES, PREPARATION OF SAME, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-07-11 | — | — | US | disclosed |
| EP-2521725-A1 | ARYLSULFONAMIDE PYRIDINE-PYRIDINONE DERIVATIVES, PREPARATION OF SAME, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-11-14 | — | — | EP | disclosed |
| WO-2011083275-A1 | ARYLSULFONAMIDE PYRIDINE-PYRIDINONE DERIVATIVES, PREPARATION OF SAME, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178472-A1 | ARYLSULFONAMIDE PYRIDINE-PYRIDINONE DERIVATIVES, PREPARATION OF SAME, AND THERAPEUTIC USE THEREOF | NDUFS2, NDUFS6, NDUFS3 | MCL1 3209/4885HPGD 578/4885TSHR 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.